



**Non WHO Reference Material  
2nd Pneumococcal QC Serum Panel  
NIBSC code: 12/278  
Instructions for use  
(Version 3.0, Dated 19/10/2017)**

**This material is not for in vitro diagnostic use.**

#### 1. INTENDED USE

This set of ampoules contains one ampoule of each of the following pneumococcal QC sera: 96/728, 96/732, 96/736, 96/746, 96/756, 96/758, 96/760, 96/762, 96/770, 96/772, 96/774 and 96/776. The material in each ampoule is the residue from freeze-drying defibrinated plasma from volunteers after immunisation with 23-valent pneumococcal polysaccharide vaccine. These reagents are for reference purposes only and are intended for use in assays to investigate the human immune response to pneumococcal polysaccharides.

#### 2. CAUTION

**This preparation is not for administration to humans or animals in the human food chain**

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA.

#### 3. UNITAGE

Assignments of IgG antibody concentrations to pneumococcal types was made by comparison to the 1st anti pneumococcal serum international standard 007sp, when the test sera are absorbed with both C and 22F polysaccharides [1, 2 and 3]. Please see table on page 2.

#### 4. CONTENTS

Country of origin of biological material: United Kingdom.  
Each ampoule contains the freeze-dried powder from 2ml of defibrinated plasma.

#### 5. STORAGE

Lyophilised serum should remain stable at room temperature but as a precautionary measure for prolonged storage ampoules should be kept in a cold and dark environment.

**Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.**

#### 6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufacturers instructions provided with the ampoule breaker.

#### 7. USE OF MATERIAL

**No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution**

Resuspend the contents of the ampoule in 2ml of sterile distilled water. The reconstituted material should be frozen at -20°C or below, preferably in aliquots to avoid excessive cycles of temperature change during prolonged use. Experience suggests that this material is stable when stored under these conditions, but the stability of samples is currently being monitored so that a shelf life may be assigned to the standard in due course.

#### 8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

Freeze-dried serum standards are expected to undergo negligible loss of activity during long term storage at the indicated storage temperature [2]. Long term storage after reconstitution (at +4°C or frozen) is yet to be established. Once reconstituted, users should determine the stability of the material according to their own method of preparation, storage and use. Users who have data supporting any changes in the characteristics of this material are encouraged to contact NIBSC.

#### 9. REFERENCES

1. Goldblatt D, et al. 2011. Establishment of a new human pneumococcal standard reference serum, 007sp. CVI 18:1728-1736.

2. Goldblatt D, et al. 2015. Assignment of Weight-Based Antibody Units for Seven Additional Serotypes to a Human Pneumococcal Standard Reference Serum, 007sp. CVI 22:1154-1159.

3. Goldblatt D, et al. 2017. Assignment of weight-based antibody units for four additional serotypes to a human anti-pneumococcal standard reference serum 007sp. CVI doi:10.1128/CVI.00194-17

Jerne NK and Perry WLM. The Stability of Biological Standards, Bull. Wld. Hlth. Org. 1956, vol. 14 pp 167-182.

WHO Technical Report Series, No. 927, 2005, Annex 2.

#### 10. ACKNOWLEDGEMENTS

#### 11. FURTHER INFORMATION

Further information can be obtained as follows:  
This material: [enquiries@nibsc.org](mailto:enquiries@nibsc.org)  
WHO Biological Standards:  
<http://www.who.int/biologicals/en/>  
JCTLM Higher order reference materials:  
<http://www.bipm.org/en/committees/jc/jctlm/>  
Derivation of International Units:  
[http://www.nibsc.org/standardisation/international\\_standards.aspx](http://www.nibsc.org/standardisation/international_standards.aspx)  
Ordering standards from NIBSC:  
<http://www.nibsc.org/products/ordering.aspx>  
NIBSC Terms & Conditions:  
[http://www.nibsc.org/terms\\_and\\_conditions.aspx](http://www.nibsc.org/terms_and_conditions.aspx)

#### 12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to [enquiries@nibsc.org](mailto:enquiries@nibsc.org)

#### 13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly. Similarly the collaborative study organised by Prof D. Goldblatt at the Institute of Child Health, London (ICH) to determine the antibody titre of this reference material should be appropriately cited.

#### 14. MATERIAL SAFETY SHEET



Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: Freeze dried powder	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify):	
Toxicological properties	
Effects of inhalation:	Not established, avoid inhalation
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.

#### Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

#### 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at [http://www.nibsc.org/About\\_Us/Terms\\_and\\_Conditions.aspx](http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx) or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

#### 16. INFORMATION FOR CUSTOMS USE ONLY

<b>Country of origin for customs purposes*:</b> United Kingdom
* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
<b>Net weight:</b> 1g
<b>Toxicity Statement:</b> Toxicity not assessed
<b>Veterinary certificate or other statement</b> if applicable.
<b>Attached:</b> No

## 2. UNITAGE

Assigned values for 12 pneumococcal QC serum samples (determined with 007sp)

Capsular serotype	calibration serum (µg/ml)											
	96/728	96/732	96/736	96/746	96/756	96/758	96/760	96/762	96/770	96/772	96/774	96/776
1	0.19	0.23	4.84	1.22	1.79	3.71	3.81	3.14	1.92	1.46	6.93	1.07
2		1.21	45.05	1.77		50.73	112.91	5.29	78.11	33.05	0.60	
3	0.26	0.19	0.26	0.44	0.41	1.37	1.65	1.30	0.84	0.58	0.09	0.16
4	5.49	0.19	0.96	0.56	6.68	0.92	2.98	0.47	2.79	1.26	0.16	0.59
5	1.77	0.40	1.30	0.40	13.32	63.31	5.21	0.54	2.86	3.30	0.49	0.37
6A	0.34	0.39	1.19	0.45	4.93	3.62	1.83	0.77	3.17	2.01	0.51	0.41
6B	0.83	0.21	0.81	4.47	5.34	9.81	1.37	0.47	9.75	1.95	0.52	2.39
7F	0.97	1.74	4.76	1.46	2.20	10.84	30.79	4.08	7.35	4.09	0.69	0.31
8	2.54	1.49	4.07	2.27	19.86	2.46	17.15	1.83	14.08	6.22	4.68	2.10
9N		2.00	1.66	8.05		3.12	10.01	0.88	13.44	3.06	1.82	
9V	2.34	0.27	0.51	3.94	5.50	5.01	1.49	0.48	3.51	2.05	3.14	0.59
10A	0.09	0.47	0.19	1.68	1.01	85.86	13.00	0.19	0.57	5.85	2.02	0.37
11A	2.60	0.61	0.87	2.84	3.42	8.99	5.48	2.01	2.01	3.49	0.78	0.42
12F	1.73	0.58	3.93	1.51	1.97	6.00	4.03	0.24	1.22	0.68	0.22	0.20
14	12.69	1.49	18.87	13.47	56.30	109.50	13.64	5.03	105.27	1.86	3.38	26.12
15B	3.42	1.57	0.63	12.69	49.31	74.23	10.43	5.66	170.62	2.67	3.66	10.94
17F		1.36	9.65	3.56		22.46	22.37	0.38	1.49	21.36	2.55	
18C	1.88	0.52	1.85	0.84	7.48	14.12	3.02	0.40	3.76	2.03	0.23	0.35
19A	6.58	1.89	1.91	1.73	41.86	8.27	10.27	4.55	7.99	18.45	0.36	1.89
19F	8.29	0.67	0.88	6.43	10.46	10.73	6.29	2.86	7.04	6.56	0.44	0.60
20A		6.17	0.93	1.56		5.76	12.79	29.56	167.72	34.56	1.48	
22F	3.95	0.20	0.90	0.66	4.42	2.23	6.33	0.98	2.26	2.17	5.12	2.42
23F	5.31	0.15	0.42	1.89	5.06	24.66	1.91	0.72	12.06	3.13	1.96	0.49
33F	8.69	2.90	3.31	0.78	16.83	9.99	16.43	1.07	21.20	3.51	1.87	1.59